Neurotech’s NTI164 Receives EU Orphan Drug Designation for Rett Syndrome

Neurotech International Ltd. ( (AU:NTI) ) has shared an update.

Neurotech International Limited has announced that the European Commission has granted Orphan Drug Designation for its lead candidate, NTI164, for the treatment of Rett Syndrome. This designation provides the company with several development incentives, including market exclusivity in the EU, reduced regulatory fees, and access to EU research funding. This milestone complements a similar designation by the US FDA, enhancing Neurotech’s position in major global markets and supporting its mission to address significant unmet needs in the treatment of rare neurological disorders.

More about Neurotech International Ltd.

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on developing treatments for pediatric neurological disorders. Their primary product, NTI164, is an oral cannabinoid drug therapy that has shown significant clinical benefits in trials for Autism Spectrum Disorder and other neurological conditions.

YTD Price Performance: -43.64%

Average Trading Volume: 698,748

Technical Sentiment Signal: Buy

Current Market Cap: A$32.31M

See more data about NTI stock on TipRanks’ Stock Analysis page.